Evidence map›Paper›PMID 41331311›Full record

ArticleScientific reports2025

Altered glycolipid metabolism during acute kidney injury exacerbates renal inflammation.

Akinori Osada, Miyako Tanaka, Yuki Sugiura, Xunmei Yuan, Shinji Yamashita, Kozue Ochi, Hiro Kohda, Ayaka Ito, Shiori Go, Tetsuya Okajima and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Akinori OsadaDepartment of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
Miyako TanakaDepartment of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan. tanaka@riem.nagoya-u.ac.jp.
Yuki SugiuraCenter for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Xunmei YuanDepartment of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
Shinji YamashitaDepartment of Life and Food Sciences, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Japan.
Kozue OchiDepartment of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
Hiro KohdaDepartment of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
Ayaka ItoDepartment of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
Shiori GoInstitute for Glyco-Core Research, Nagoya University, Nagoya, Japan.
Tetsuya OkajimaDepartment of Molecular and Cellular Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kenji KadomatsuInstitute for Glyco-Core Research, Nagoya University, Nagoya, Japan.
Motoko YanagitaDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kazuhiro FuruhashiDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shoichi MaruyamaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takayoshi SuganamiDepartment of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan. suganami@riem.nagoya-u.ac.jp.

Funding

Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan 24K10076 and 23H04776Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan 24KK0150, 23K27377, and 22K19524Japan Agency for Medical Research and Development CREST [JP24gm1210009s0106] and LEAP [24gm0010011s0102]Japan Agency for Medical Research and Development Research Program on Hepatitis [JP24fk0210154s0501]
6 · The paper itself

Abstract

Acute kidney injury (AKI) can progress to chronic kidney disease (CKD), via a mechanism that is still largely unknown. We previously reported that glucosylceramide (GlcCer) acts as a damage-associated molecular pattern (DAMP) during AKI. Here, we demonstrate that renal GlcCer levels increase persistently during AKI, primarily due to oxidative stress-mediated downregulation of β-1,4-galactosyltransferase 5 (B4galt5) in proximal tubules. Using mass spectrometry, we showed that GlcCer specifically accumulated in damaged proximal tubules. Among the enzymes involved in GlcCer metabolism, B4galt5 was predominantly expressed in proximal tubules and its expression was consistently downregulated across multiple AKI models. Knockdown of B4galt5 alone was sufficient to increase GlcCer levels in cultured proximal tubular cells. Moreover, in vivo administration of GlcCer combined with free cholesterol triggered inflammatory responses via the innate immune receptor macrophage-inducible C-type lectin (Mincle). These inflammatory responses were almost abolished in Mincle-deficient mice, suggesting a specific GlcCer-Mincle pathway. Our findings indicate that B4galt5 plays a critical role in GlcCer accumulation in necrotic tubules following AKI. Specifically, we propose that dying proximal tubules alter their glycolipid metabolism to generate DAMPs, highlighting B4galt5 as a potential therapeutic target for preventing the AKI-to-CKD transition.

Indexed as

Acute Kidney InjuryGlucosylceramidesGlycolipidsInflammationAnimalsDisease Models, AnimalGalactosyltransferasesHumansKidney Tubules, ProximalLectins, C-TypeMaleMembrane ProteinsMiceMice, Inbred C57BLMice, KnockoutOxidative StressClecsf8 protein, mouseGalactosyltransferasesGlucosylceramidesGlycolipidsLectins, C-TypeMembrane Proteins

Identifiers

PMID41331311
PMCPMC12765023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.